WH244 1mg | Purity Not Available
Selleck Chemicals
WH244 is a second-generation PROTAC that selectively degrades the anti-apoptotic proteins BCL-xL and BCL-2 with a DC50 of 0.6 nM for BCL-xL and 7.4 nM for BCL-2.
More Information Supplier PageWH244 is a second-generation PROTAC that selectively degrades the anti-apoptotic proteins BCL-xL and BCL-2 with a DC50 of 0.6 nM for BCL-xL and 7.4 nM for BCL-2.
More Information Supplier PageSPA-10091-HCl is a degrader of DOT1L that selectively degrades DOT1L protein through the nuclear ubiquitin-proteasome pathway, thereby suppressing H3K79 methylation in CRPC cells. It also inhibits DOT1L enzymatic activity with an IC50 of 0.87 μM, induces apoptosis, and significantly reduces tumor growth in vivo.
More Information Supplier PageGDC-2992 (RO7656594, Compound 28A) is an orally active degrader of androgen receptor (AR) with a DC50 of 2.7 nM. It binds to AR and cereblon (CRBN), inducing AR ubiquitination and degradation. GDC-2992 also inhibits cell proliferation in VCaP cells and exhibits potential to reduce treatment resistance and disease relapse in prostate cancer.
More Information Supplier PageGolidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
More Information Supplier PageGolidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
More Information Supplier PageGolidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
More Information Supplier PageZ57346765 hydrochloride is an inhibitor of phosphoglycerate kinase 1 (PGK1) that binds to the ADP-binding pocket with a KD value of 2.09 × 10⁻⁵ M, reducing PGK1 metabolic enzyme activity, glucose consumption, and lactate production. It also inhibits DNA replication, impairs DNA damage repair, and induces cell cycle arrest in kidney renal clear cell carcinoma (KIRC) […]
More Information Supplier PageZ57346765 hydrochloride is an inhibitor of phosphoglycerate kinase 1 (PGK1) that binds to the ADP-binding pocket with a KD value of 2.09 × 10⁻⁵ M, reducing PGK1 metabolic enzyme activity, glucose consumption, and lactate production. It also inhibits DNA replication, impairs DNA damage repair, and induces cell cycle arrest in kidney renal clear cell carcinoma (KIRC) […]
More Information Supplier PageGolidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
More Information Supplier PageZ57346765 hydrochloride is an inhibitor of phosphoglycerate kinase 1 (PGK1) that binds to the ADP-binding pocket with a KD value of 2.09 × 10⁻⁵ M, reducing PGK1 metabolic enzyme activity, glucose consumption, and lactate production. It also inhibits DNA replication, impairs DNA damage repair, and induces cell cycle arrest in kidney renal clear cell carcinoma (KIRC) […]
More Information Supplier Page